Registries offer insights which helps clinicians and institutions to improve the delivery of healthcare. They also act as a tool for pharmaceutical companies to gather evidence of their drugs’ effectiveness for approved indications and potentially new indications, thus encouraging further research.
Data collected by the Save Sight Registries provide benefits for our patients and other stakeholders.
Graphs of long-term treatment outcomes and progression of eye diseases can be generated in real-time by clinicians and shown to patients.
-> link to” Patient progress tracked graphically” in FOR CLINICIANS TAB
Reports charting patient progress (individual eyes treated) can be generated simply with the click of a button and enable clinicians to track real-time outcomes at the individual patient or clinic level
Encourages scientific collaboration and dissemination of key clinical findings
“From my perspective FRB! System has been a real God send. Without FRB! I would not be able to follow the progress (or lack of!) or audit the seemingly hundreds of patients who are under my care within the public system”
“This data is Gold! Thank you so much”
“There is a growing head of steam recognising the worth of FRB! as a tool to provide the ongoing outcome audit we so desperately need here”
“Thank you very much for your comprehensive introduction to the FRB project…. The practical and scientific values of the project has become clear to us as well as easiness of data entry (just a few seconds!)”
“Thanks a lot for the interim report, which is very comprehensive and inspiring”
Efficient capture of high quality data on Outcomes of treatment for macular diseases: The Fight Retinal Blindness! Project
Prospective Audit of Exudative Age-Related Macular Degeneration: 12-month Outcomes in Treatment-Naïve eyes. FRB! Project report #2.
|Invest Ophthalmol Vis Sci||2013 August||http://www.ncbi.nlm.nih.gov/pubmed/?term=Prospective+Audit+of+Exudative+Age-Related+Macular+Degeneration%3A+12-month+Outcomes+in+Treatment-Na%C3%AFve+eyes.+FRB!+Project+report+%232|
Outcomes of persistently active neovascular age related Macular degeneration treated with vegf Inhibitors: observational study data
|Brit J Ophthalmol||2014 March||http://www.ncbi.nlm.nih.gov/pubmed/?term=Outcomes+of+persistently+active+neovascular+age+related+Macular+degeneration+treated+with+vegf+Inhibitors%3A+observational+study+data|
Comparison of Outcomes from a Phase 3 Study of Age-Related Macular Degeneration with a Matched, Observational Cohort
Intravitreal Therapy in Bilateral Neovascular Age-Related Macular Degeneration
Time to initial clinician-reported inactivation of neovascular age-related macular degeneration
Two Year Outcomes of “Treat And Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration
Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study
Effects of Switching from Ranibizumab to Aflibercept in Eyes with Exudative Age-Related Macular Degeneration
|Brit J Ophthalmol||2016 March||http://www.ncbi.nlm.nih.gov/pubmed/26994110|
Treatment patterns and visual outcomes during the maintenance phase of treat and extend therapy for age-related macular degeneration
Twelve-month outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration. Data from an observational study.
Two Year Outcomes of “Treat and Extend” Intravitreal Therapy Using Aflibercept for Neovascular Age-Related Macular Degeneration
Ranibizumab and aflibercept for the treatment of pigment epithelial detachment in neovascular age-related macular degeneration: data from an observational study
Incidence and outcomes of infectious and non-infectious endophthalmitis following intravitreal injections for age-related macular degeneration
Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration
|Clinical and Experimental Ophthalmology||2017|